234 Church Street
About Biohaven Pharma
220 articles with Biohaven Pharma
3/15/2021It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.
- NURTEC ODT obtained market authorization in the United Arab Emirates, along with the recent approval in Israel - NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT)
Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital
Biohaven's verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
Biohaven reports NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
-Biohaven's proprietary MATE™ conjugation platform has been used to generate a new class of antibody-based therapies to target COVID-19 -BHV-1200, a COVID-19 targeting MATE compound, recently completed in vitro testing that demonstrated activity against SARS-CoV-2 wild-type as well as mutants associated with reduced susceptibility to therapeutic monoclonal antibodies and emerging strains
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the advancement of several important steps that underscore the company's commitment to sound Environmental, Social and Governance ("ESG")
Biohaven Pharmaceutical Holding Company Ltd.today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the fourth quarter of 2020.
1/25/2021With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
Biohaven Pharmaceuticals announced that Cody Ware will pilot the Nurtec® ODT #51 Chevrolet Camaro for Rick Ware Racing during the 2021 NASCAR Cup Series season.
Biohaven Pharmaceuticals announced that Nurtec® ODT will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona.
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
Sosei Group Corporation announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd..
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
Weill Cornell Medicine's Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque psoriasis
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
- National Ataxia Foundation (NAF) Drug Development Collaborative to cultivate resources that facilitate research and development of new potential treatments for Ataxia, a set of severe and debilitating neurodegenerative diseases - Biohaven Pharmaceuticals, the first industry sponsor of the Collaborative, is currently conducting a Phase 3 clinical trial of troriluzole for Spinocerebellar Ataxia (SCA)
$60.0 million Series A funding completed by Asia-Pacific subsidiary, BioShin to bring NURTEC™ ODT to an estimated 80 million migraine sufferers in China
U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine
Acceptance marks critical milestone in Biohaven's efforts to develop NURTEC ODT as a unique dual therapy for both the preventive and acute treatment of migraine NURTEC ODT 75 mg has been shown in placebo-controlled trials to return patients to normal functioning within 60 minutes when used in the acute treatment of migraine and has also been shown to reduce monthly migraine days at the same 75 mg dose administered every other day for preventive treatment
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
Initiating NURTEC ODT Phase 3 study for acute migraine in China and Korea, and China registrational study of troriluzole in Spinocerebellar Ataxia in 4Q20
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
- Investigational New Drug (IND) application was authorized to proceed by the US FDA for human dosing with oral zavegepant - Biohaven achieved first in human dosing with oral zavegepant to assess the safety and pharmacokinetic profile - Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist in development for both migraine and non-migraine indications including COVID-19 associated lung inflammation
- NURTEC™ ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share - Company well-capitalized with recent non-dilutive financing of up to $950M from Sixth Street term loan and Royalty Pharma funding agreement - Remains on timelines for NURTEC ODT sNDA filing for prevention of migraine in the coming months; additionally, completion of troriluzole Alzheimer's Disease Phase 2/3 trial in 4Q2020, and topline resu
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced that it entered into a $500 million non-dilutive term loan financing facility with Six